Silence Therapeutics Plc

good day and thank you for standing by welcome to the silence therapeutics 2022 annual results conference call and webcast at this time all participants are in a listen only mode after the speaker's presentation there'll be a question and answer session to ask a question during the session you will need to press star one and one on your telephone you will then hear an automated message advising your hand is raised to withdraw your question please press star one and one again Participants can also submit questions through the webcast platform, which will be answered by the company at a later date. As a reminder, listeners should join the call through either the webcast or the phone lines for the best viewing experience. Please be advised that today's conference is being recorded. I will hand over to Dem Hopkins, Head of IR and Corporate Communications to open the webcast. Please go ahead.

Good morning and good afternoon, everyone. Thank you for joining us today. My name is Jen Hopkins, Head of Investor Relations and Corporate Communications at Silence. Joining me today on the call are Craig Tooman, our President and CEO, who will provide an update on the business, Rhonda Helms, our CFO, who will review our financial performance, and Giles Campion, our Head of R&D, who will provide an update on our clinical programs. For those of you participating via conference call, the accompanying slides can be accessed by going to the Investor section of our corporate website at www.silence-therapeutics.com. Turning to slide two, I'd like to remind you that during today's call, management will make projections or other forward-looking statements regarding anticipated future events or the future financial performance of the company, including clinical development timing and objectives, the therapeutic potential of our product candidates, our operational plans and strategies, anticipated milestone payments, anticipated operating and capital expenditures, business prospects, and projected cash runway. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those discussed in our most recent annual report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to Craig. Craig?

Thank you, Jim, and welcome, everyone. Thank you for joining us today. 2022 was an exceptional year at Silence, where we delivered impressive clinical data with SOM360, now known as or LASRAN, for high LP little a and made important advancements across our broader pipeline of SIRNA therapeutics. With Zolaciran, which is a wholly-owned program, we reported up to 98% efficacy in the Apollo study with strong durability after a single dose. These results were simultaneously presented at the ACC 2022 Annual Meeting and published in JAMA, a rare achievement, particularly for a Phase I study. This speaks to how impressive these data were and the growing recognition that Lp is a major cardiovascular risk factor that needs to be addressed. We are very pleased with the overall enthusiasm for this program and believe we have opportunities to differentiate in the category. We also continue to progress our second wholly-owned program, SLN124, in the clinic and reported encouraging preliminary safety results in the Gemini 2 Phase 1 Thalassemia Study. The SLN360, Zerlaciran, and SLN124 programs are great examples of how we can use our proprietary mRNAi gold platform to address a broad range of genetic diseases. We made tremendous progress advancing our platform in the clinic in 2022, and expect to build on that positive momentum in 2023 and beyond. With our partner programs, we started working on the second target under our HANSO Pharma collaboration in December, moved SLN501 into the clinic with MelanCross, and advanced work with AstraZeneca on multiple targets. While we are limited in what we can disclose with our partner programs, I can tell you I'm very encouraged by the continued progress across our collaborations, and we expect to communicate more updates this year. In January, we announced that we initiated both the SLN360 Zolaceram Phase II ASCVD study and the SLN124PV study. Looking forward to the rest of 2023, We have several important milestones, including top-line data from the multiple-dose portion of the Apollo study and high Lp and top-line data from the multiple-dose portion of the Gemini 2 study and thalassemia. We also expect to complete enrollment in the Xerlazeron Phase 2 ASCVD study by the end of the year. We look forward to another year of strong execution in 2023. As we continue to advance our clinical programs across both our proprietary and partner programs, our technology is increasingly being acknowledged as a platform. We look forward to fully harnessing this technology. With that, I'll now turn the call over to Rhonda. Rhonda?